{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:38:17Z","timestamp":1794562697441,"version":"4.9.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["564906"],"award-info":[{"award-number":["564906"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["564906"],"award-info":[{"award-number":["564906"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["564906"],"award-info":[{"award-number":["564906"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["564906"],"award-info":[{"award-number":["564906"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["564906"],"award-info":[{"award-number":["564906"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["564906"],"award-info":[{"award-number":["564906"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>HPV16\/18 detection may improve cervical cancer risk stratification and better guide which HPV-positive women warrant immediate colposcopy\/biopsy. We estimated risks of cervical precancer and cancer by HPV genotype and cytology during the implementation phase of primary HPV testing in Norway.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 3111 women, aged 34\u201369 years, testing HPV-positive at baseline and undergoing cytology testing from February 2015 to April 2018 had data available for analysis. Risk estimates with 95% confidence intervals (95%CIs) of cervical intraepithelial neoplasia grade 3 or more severe (CIN3+) were estimated for cytology results and HPV genotypes (HPV16, HPV18, and other high-risk HPV).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>CIN3+ risks were higher for HPV16\/18 than other high-risk HPV genotypes. Among women with any cytologic abnormality [atypical squamous cells of undetermined significance or worse], immediate risks were 57.8% (95%CI\u2009=\u200953.0\u201362.6%) for HPV16, 40.2% (95%CI\u2009=\u200932.3\u201349.2%) for HPV18, and 31.4% (95%CI\u2009=\u200928.7\u201334.3%) for other high-risk HPV. Among those with normal cytology, CIN3+ risks were 19.9% (95%CI\u2009=\u200915.0\u201326.1%) for HPV16 positives, 10.8% (95%CI\u2009=\u20095.6\u201320.5%) for HPV18 positives, and 5.5% (95%CI\u2009=\u20094.2\u20137.1%) for other high-risk HPV.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The benefits and harms of managing women based on HPV positivity and cytology results can be better balanced by inclusion of HPV genotyping in screening and choosing more conservative management for other high-risk HPV compared to HPV16\/18.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-020-0790-1","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T23:07:02Z","timestamp":1585868822000},"page":"1715-1723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening"],"prefix":"10.1038","volume":"122","author":[{"given":"Dana","family":"Hashim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Enges\u00e6ter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gry","family":"Baadstrand Skare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E.","family":"Castle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9096-5257","authenticated-orcid":false,"given":"Tone","family":"Bj\u00f8rge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameli","family":"Trop\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4100-4855","authenticated-orcid":false,"given":"Mari","family":"Nyg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,3]]},"reference":[{"key":"790_CR1","doi-asserted-by":"publisher","first-page":"b2569","DOI":"10.1136\/bmj.b2569","volume":"339","author":"PE Castle","year":"2009","unstructured":"Castle, P. E., Rodriguez, A. C., Burk, R. D., Herrero, R., Wacholder, S., Alfaro, M. et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 339, b2569 (2009).","journal-title":"BMJ"},{"key":"790_CR2","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1093\/jnci\/djq356","volume":"102","author":"SK Kjaer","year":"2010","unstructured":"Kjaer, S. K., Frederiksen, K., Munk, C. & Iftner, T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J. Natl Cancer Inst. 102, 1478\u20131488 (2010).","journal-title":"J. Natl Cancer Inst."},{"key":"790_CR3","doi-asserted-by":"publisher","first-page":"698","DOI":"10.7326\/0003-4819-155-10-201111150-00377","volume":"155","author":"KK Vesco","year":"2011","unstructured":"Vesco, K. K., Whitlock, E. P., Eder, M., Burda, B. U., Senger, C. A. & Lutz, K. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 155, 698\u2013705 (2011).","journal-title":"Ann. Intern. Med."},{"key":"790_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco, G., Dillner, J., Elfstrom, K. M., Tunesi, S., Snijders, P. J., Arbyn, M. et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383, 524\u2013532 (2014).","journal-title":"Lancet"},{"key":"790_CR5","doi-asserted-by":"publisher","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","volume":"30","author":"M Arbyn","year":"2012","unstructured":"Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J., Poljak, M., Ogilvie, G. et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30, F88\u2013F99 (2012).","journal-title":"Vaccine"},{"key":"790_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.7326\/0003-4819-155-10-201111150-00376","volume":"155","author":"EP Whitlock","year":"2011","unstructured":"Whitlock, E. P., Vesco, K. K., Eder, M., Lin, J. S., Senger, C. A. & Burda, B. U. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 155, 687\u2013697 (2011).","journal-title":"Ann. Intern. Med."},{"key":"790_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pvr.2015.06.006","volume":"1","author":"L von Karsa","year":"2015","unstructured":"von Karsa, L., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S. et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 1, 22\u201331 (2015).","journal-title":"Papillomavirus Res."},{"key":"790_CR8","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa073204","volume":"357","author":"P Naucler","year":"2007","unstructured":"Naucler, P., Ryd, W., Tornberg, S., Strand, A., Wadell, G., Elfgren, K. et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357, 1589\u20131597 (2007).","journal-title":"N. Engl. J. Med."},{"key":"790_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S1470-2045(09)70385-7","volume":"11","author":"PE Castle","year":"2010","unstructured":"Castle, P. E. & Katki, H. A. Benefits and risks of HPV testing in cervical cancer screening. Lancet Oncol. 11, 214\u2013215 (2010).","journal-title":"Lancet Oncol."},{"key":"790_CR10","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jcv.2015.11.015","volume":"76","author":"N Wentzensen","year":"2016","unstructured":"Wentzensen, N., Schiffman, M., Palmer, T. & Arbyn, M. Triage of HPV positive women in cervical cancer screening. J. Clin. Virol. 76, S49\u2013s55 (2016).","journal-title":"J. Clin. Virol."},{"key":"790_CR11","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/ijc.30926","volume":"141","author":"LS Velentzis","year":"2017","unstructured":"Velentzis, L. S., Caruana, M., Simms, K. T., Lew, J. B., Shi, J. F., Saville, M. et al. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country. Int. J. Cancer 141, 2410\u20132422 (2017).","journal-title":"Int. J. Cancer"},{"key":"790_CR12","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1097\/LGT.0b013e318285423c","volume":"17","author":"HA Katki","year":"2013","unstructured":"Katki, H. A., Schiffman, M., Castle, P. E., Fetterman, B., Poitras, N. E., Lorey, T. et al. Benchmarking CIN3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J. Low. Genit. Trac. Dis. 17, S28 (2013).","journal-title":"J. Low. Genit. Trac. Dis."},{"key":"790_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1309\/AJCPTUS5EXAS6DKZ","volume":"136","author":"TC Wright Jr.","year":"2011","unstructured":"Wright, T. C. Jr., Stoler, M. H., Sharma, A., Zhang, G., Behrens, C., Wright, T. L. et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am. J. Clin. Pathol. 136, 578\u2013586 (2011).","journal-title":"Am. J. Clin. Pathol."},{"key":"790_CR14","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1086\/507909","volume":"194","author":"CM Wheeler","year":"2006","unstructured":"Wheeler, C. M., Hunt, W. C., Schiffman, M. & Castle, P. E. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J. Infect. Dis. 194, 1291\u20131299 (2006).","journal-title":"J. Infect. Dis."},{"key":"790_CR15","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1093\/jnci\/dji186","volume":"97","author":"PE Castle","year":"2005","unstructured":"Castle, P. E., Solomon, D., Schiffman, M. & Wheeler, C. M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl Cancer Inst. 97, 1066\u20131071 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"790_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3322\/caac.21139","volume":"62","author":"D Saslow","year":"2012","unstructured":"Saslow, D., Solomon, D., Lawson, H. W., Killackey, M., Kulasingam, S. L., Cain, J. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 62, 147\u2013172 (2012).","journal-title":"CA Cancer J. Clin."},{"key":"790_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1309\/AJCPLCD8TTOMLJTB","volume":"143","author":"PE Castle","year":"2015","unstructured":"Castle, P. E., Cuzick, J., Stoler, M. H., Wright, T. C. Jr., Reid, J. L., Dockter, J. et al. Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study. Am. J. Clin. Pathol. 143, 160\u2013167 (2015).","journal-title":"Am. J. Clin. Pathol."},{"key":"790_CR18","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S de Sanjose","year":"2010","unstructured":"de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B. et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 11, 1048\u20131056 (2010).","journal-title":"Lancet Oncol."},{"key":"790_CR19","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/jnci\/dji187","volume":"97","author":"MJ Khan","year":"2005","unstructured":"Khan, M. J., Castle, P. E., Lorincz, A. T., Wacholder, S., Sherman, M., Scott, D. R. et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst. 97, 1072\u20131079 (2005).","journal-title":"J. Natl Cancer Inst."},{"key":"790_CR20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ijc.27680","volume":"132","author":"M Hosaka","year":"2013","unstructured":"Hosaka, M., Fujita, H., Hanley, S. J., Sasaki, T., Shirakawa, Y., Abiko, M. et al. Incidence risk of cervical intraepithelial neoplasia 3 or more severe lesions is a function of human papillomavirus genotypes and severity of cytological and histological abnormalities in adult Japanese women. Int. J. Cancer 132, 327\u2013334 (2013).","journal-title":"Int. J. Cancer"},{"key":"790_CR21","doi-asserted-by":"publisher","first-page":"46.e1","DOI":"10.1016\/j.ajog.2011.07.024","volume":"206","author":"TC Wright Jr.","year":"2012","unstructured":"Wright, T. C. Jr., Stoler, M. H., Behrens, C. M., Apple, R., Derion, T. & Wright, T. L. The ATHENA human papillomavirus study: design, methods, and baseline results. Am. J. Obstet. Gynecol. 206, 46.e1\u2013.e11 (2012).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"790_CR22","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1002\/ijc.32004","volume":"144","author":"NJ Polman","year":"2019","unstructured":"Polman, N. J., Veldhuijzen, N. J., Heideman, D. A. M., Snijders, P. J. F., Meijer, C. & Berkhof, J. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds. International journal of cancer. Int. J. Cancer 144, 2339\u20132346 (2019).","journal-title":"Int. J. Cancer"},{"key":"790_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.7326\/M15-2735","volume":"166","author":"M Arbyn","year":"2017","unstructured":"Arbyn, M., Xu, L., Verdoodt, F., Cuzick, J., Szarewski, A., Belinson, J. L. et al. Genotyping for human papillomavirus types 16 and 18 in women with minor cervical lesions: a systematic review and meta-analysis. Ann. Intern. Med. 166, 118\u2013127 (2017).","journal-title":"Ann. Intern. Med."},{"key":"790_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-2028-7","volume":"16","author":"B Engesaeter","year":"2016","unstructured":"Engesaeter, B., van Diermen Hidle, B., Hansen, M., Moltu, P., Staby, K. M., Borchgrevink-Persen, S. et al. Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study. BMC Infect. Dis. 16, 698 (2016).","journal-title":"BMC Infect. Dis."},{"key":"790_CR25","unstructured":"Laboratories A. Realtime High Risk HPV [Website]. https:\/\/www.molecular.abbott\/int\/en\/products\/infectious-disease\/realtime-high-risk-hpv (Abbott, Abbott Park, Illinois, 2018)."},{"key":"790_CR26","unstructured":"Diagnostics R. M. cobas\u00ae HPV 2018. https:\/\/molecular.roche.com\/assays\/cobas-hpv-test\/ (2018)."},{"key":"790_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-2042-8","volume-title":"The Bethesda System for reporting cervical cytology: definitions, criteria, and explanatory notes.","author":"D Solomon","year":"2004","unstructured":"Solomon, D. & Nayar, R. The Bethesda System for reporting cervical cytology: definitions, criteria, and explanatory notes. 2 ed. (Springer-Verlag New-York, Inc., New-York, 2004).","edition":"2 ed."},{"key":"790_CR28","unstructured":"Trope A., Engesaeter B., Nygard M., Andreassen T., Lonnberg S. & Ursin G. [Safe implementation of HPV testing in the Norwegian Cervical Cancer Screening Programme]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 137, (2017)."},{"key":"790_CR29","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1080\/0284186X.2018.1497296","volume":"57","author":"MK Leinonen","year":"2018","unstructured":"Leinonen, M. K., Hansen, S. A., Skare, G. B., Skaaret, I. B., Silva, M., Johannesen, T. B. et al. Low proportion of unreported cervical treatments in the cancer registry of Norway between 1998 and 2013. Acta Oncologica 57, 1663\u20131670 (2018).","journal-title":"Acta Oncologica"},{"key":"790_CR30","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.ejca.2008.10.037","volume":"45","author":"IK Larsen","year":"2009","unstructured":"Larsen, I. K., Smastuen, M., Johannesen, T. B., Langmark, F., Parkin, D. M., Bray, F. et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur. J. Cancer 45, 1218\u20131231 (2009).","journal-title":"Eur. J. Cancer"},{"key":"790_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1136\/jms.9.2.86","volume":"9","author":"JF Nygard","year":"2002","unstructured":"Nygard, J. F., Skare, G. B. & Thoresen, S. O. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J. Med. Screen. 9, 86\u201391 (2002).","journal-title":"J. Med. Screen."},{"key":"790_CR32","unstructured":"Tavassoli, F. A., Devilee, P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003."},{"key":"790_CR33","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/ijc.30375","volume":"139","author":"M Schiffman","year":"2016","unstructured":"Schiffman, M., Hyun, N., Raine-Bennett, T. R., Katki, H., Fetterman, B., Gage, J. C. et al. A cohort study of cervical screening using partial HPV typing and cytology triage. Int. J. Cancer 139, 2606\u20132615 (2016).","journal-title":"Int. J. Cancer"},{"key":"790_CR34","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","volume":"12","author":"PE Castle","year":"2011","unstructured":"Castle, P. E., Stoler, M. H., Wright, T. C. Jr., Sharma, A., Wright, T. L. & Behrens, C. M. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 12, 880\u2013890 (2011).","journal-title":"Lancet Oncol."},{"key":"790_CR35","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1309\/AJCPZ5JY6FCVNMOT","volume":"135","author":"MH Stoler","year":"2011","unstructured":"Stoler, M. H., Wright, T. C. Jr., Sharma, A., Apple, R., Gutekunst, K. & Wright, T. L. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am. J. Clin. Pathol. 135, 468\u2013475 (2011).","journal-title":"Am. J. Clin. Pathol."},{"key":"790_CR36","doi-asserted-by":"publisher","first-page":"8578","DOI":"10.1158\/0008-5472.CAN-10-1188","volume":"70","author":"N Wentzensen","year":"2010","unstructured":"Wentzensen, N., Wilson, L. E., Wheeler, C. M., Carreon, J. D., Gravitt, P. E., Schiffman, M. et al. Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study. Cancer Res. 70, 8578\u20138586 (2010).","journal-title":"Cancer Res."},{"key":"790_CR37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1309\/PT3PNC1QL2F4D2VL","volume":"127","author":"PE Castle","year":"2007","unstructured":"Castle, P. E., Stoler, M. H., Solomon, D. & Schiffman, M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am. J. Clin. Pathol. 127, 805\u2013815 (2007).","journal-title":"Am. J. Clin. Pathol."},{"key":"790_CR38","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1001\/jama.285.11.1500","volume":"285","author":"MH Stoler","year":"2001","unstructured":"Stoler, M. H. & Schiffman, M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 285, 1500\u20131505 (2001).","journal-title":"JAMA"},{"key":"790_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/AOG.0b013e31818f5008","volume":"113","author":"PE Castle","year":"2009","unstructured":"Castle, P. E., Schiffman, M., Wheeler, C. M. & Solomon, D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet. Gynecol. 113, 18\u201325 (2009).","journal-title":"Obstet. Gynecol."},{"key":"790_CR40","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/AOG.0b013e3181fe777f","volume":"116","author":"AB Moscicki","year":"2010","unstructured":"Moscicki, A. B., Ma, Y., Wibbelsman, C., Darragh, T. M., Powers, A., Farhat, S. et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet. Gynecol. 116, 1373\u20131380 (2010).","journal-title":"Obstet. Gynecol."},{"key":"790_CR41","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457\u2013481 (1958).","journal-title":"J. Am. Stat. Assoc."},{"key":"790_CR42","unstructured":"Marubini E. & Valsecchi M. G. Analysing Survival Data from Clinical Trials and Observational Studies (John Wiley & Sons, 2004)."},{"key":"790_CR43","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1097\/AOG.0000000000000458","volume":"124","author":"WK Huh","year":"2014","unstructured":"Huh, W. K., Sideri, M., Stoler, M., Zhang, G., Feldman, R. & Behrens, C. M. Relevance of random biopsy at the transformation zone when colposcopy is negative. Obstet. Gynecol. 124, 670\u2013678 (2014).","journal-title":"Obstet. Gynecol."},{"key":"790_CR44","doi-asserted-by":"publisher","first-page":"a1284","DOI":"10.1136\/bmj.a1284","volume":"337","author":"M Arbyn","year":"2008","unstructured":"Arbyn, M., Kyrgiou, M., Simoens, C., Raifu, A. O., Koliopoulos, G., Martin-Hirsch, P. et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. Bmj 337, a1284 (2008).","journal-title":"Bmj"},{"key":"790_CR45","doi-asserted-by":"publisher","first-page":"i3633","DOI":"10.1136\/bmj.i3633","volume":"354","author":"M Kyrgiou","year":"2016","unstructured":"Kyrgiou, M., Athanasiou, A., Paraskevaidi, M., Mitra, A., Kalliala, I., Martin-Hirsch, P. et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. Bmj 354, i3633 (2016).","journal-title":"Bmj"},{"key":"790_CR46","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/ijc.31883","volume":"144","author":"FL Sand","year":"2018","unstructured":"Sand, F. L., Munk, C., Frederiksen, K., Junge, J., Iftner, T., Dehlendorff, C. et al. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types. International journal of cancer. Int. J. Cancer 144, 1975\u20131982 (2018).","journal-title":"Int. J. Cancer"},{"key":"790_CR47","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/cncr.10317","volume":"96","author":"DR Scott","year":"2002","unstructured":"Scott, D. R., Hagmar, B., Maddox, P., Hjerpe, A., Dillner, J., Cuzick, J. et al. Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer 96, 14\u201320 (2002).","journal-title":"Cancer"},{"key":"790_CR48","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/LGT.0000000000000343","volume":"21","author":"M Demarco","year":"2017","unstructured":"Demarco, M., Lorey, T. S., Fetterman, B., Cheung, L. C., Guido, R. S., Wentzensen, N. et al. Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines. J. Low. Genit. Trac. Dis. 21, 261\u2013267 (2017).","journal-title":"J. Low. Genit. Trac. Dis."},{"key":"790_CR49","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","volume":"12","author":"HA Katki","year":"2011","unstructured":"Katki, H. A., Kinney, W. K., Fetterman, B., Lorey, T., Poitras, N. E., Cheung, L. et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 12, 663\u2013672 (2011).","journal-title":"Lancet Oncol."},{"key":"790_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ygyno.2016.10.031","volume":"144","author":"TC Wright Jr.","year":"2017","unstructured":"Wright, T. C. Jr., Behrens, C. M., Ranger-Moore, J., Rehm, S., Sharma, A., Stoler, M. H. et al. Triaging HPV-positive women with p16\/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Gynecologic Oncol. 144, 51\u201356 (2017).","journal-title":"Gynecologic Oncol."},{"key":"790_CR51","unstructured":"Skare, G. B., Bj\u00f8rge, T. & Trop\u00e9, A. \u00c5rsrapport 2016, Livmorhalsprogrammet (2016)."},{"key":"790_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1158\/1055-9965.EPI-13-0173","volume":"23","author":"MG Dijkstra","year":"2014","unstructured":"Dijkstra, M. G., van Niekerk, D., Rijkaart, D. C., van Kemenade, F. J., Heideman, D. A., Snijders, P. J. et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol. Biomarkers Prev. 23, 55\u201363 (2014).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"790_CR53","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/ijc.26056","volume":"130","author":"DC Rijkaart","year":"2012","unstructured":"Rijkaart, D. C., Berkhof, J., van Kemenade, F. J., Coupe, V. M. H., Hesselink, A. T., Rozendaal, L. et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int. J. cancer 130, 602\u2013610 (2012).","journal-title":"Int. J. cancer"},{"key":"790_CR54","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1158\/1055-9965.EPI-11-0206","volume":"20","author":"M Schiffman","year":"2011","unstructured":"Schiffman, M., Glass, A. G., Wentzensen, N., Rush, B. B., Castle, P. E., Scott, D. R. et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol. Biomarkers Prev. 20, 1398\u20131409 (2011).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"6","key":"790_CR55","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41416-019-0547-x","volume":"121","author":"Matejka Rebolj","year":"2019","unstructured":"Rebolj M., Brentnall A. R., Mathews C., Denton K., Holbrook M., Levine T. et al. 16\/18 genotyping in triage of persistent human papillomavirus infections with negative cytology in the English cervical screening pilot. Br. J. Cancer 121, 455\u2013463 (2019).","journal-title":"British Journal of Cancer"},{"key":"790_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/lgt.0b013e31815ea58b","volume":"12","author":"PE Castle","year":"2008","unstructured":"Castle, P. E., Sideri, M., Jeronimo, J., Solomon, D. & Schiffman, M. Risk assessment to guide the prevention of cervical cancer. J. Low. Genit. Trac. Dis. 12, 1\u20137 (2008).","journal-title":"J. Low. Genit. Trac. Dis."},{"key":"790_CR57","doi-asserted-by":"publisher","first-page":"e1002388","DOI":"10.1371\/journal.pmed.1002388","volume":"14","author":"K Canfell","year":"2017","unstructured":"Canfell, K., Caruana, M., Gebski, V., Darlington-Brown, J., Heley, S., Brotherton, J. et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Med. 14, e1002388 (2017).","journal-title":"PLoS Med."},{"key":"790_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/0284186X.2011.593547","volume":"51","author":"S Lonnberg","year":"2012","unstructured":"Lonnberg, S., Leinonen, M., Malila, N. & Anttila, A. Validation of histological diagnoses in a national cervical screening register. Acta Oncologica 51, 37\u201344 (2012).","journal-title":"Acta Oncologica"},{"key":"790_CR59","unstructured":"NCCSP NCCSP. HPV i prim\u00e6rscreening. https:\/\/www.kreftregisteret.no\/en\/screening\/Cervical-Cancer-Screening-Programme\/Helsepersonell\/screeningstrategi-og-nasjonale-retningslinjer\/hpv-i-primarscreening\/ (Cancer Registry of Norway, Oslo, Norway, 2018)."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0790-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0790-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0790-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:07:49Z","timestamp":1684616869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0790-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,5,26]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0790-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]},"assertion":[{"value":"30 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Regional Committee for Medical and Health Research Ethics (REK) in South East Norway (REK reference number 2017\/1910). REK has given exemption from the consent requirement pursuant to the Norwegian Health Research Act \u00a7 35. This exemption is provided that the research in question is of significant interest to society, and the welfare and integrity of the participants is ensured. The specific purpose of this project is to improve cervical cancer prevention and diagnose the disease earlier. The study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"All data not included in this published article are available upon reasonable request from the Cancer Registry of Norway.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"P.E.C. has received cervical screening tests and diagnostics from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation at a reduced or no cost for research. All other authors report no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work is supported by a grant from the Norwegian Cancer Society, project ID: #564905. Sponsors had no role in study design, data collection, analysis, and interpretation of data; in the writing of the report or the decision to submit the article for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}